International Journal of Clinical Pharmacology, Therapy and Toxicology 1988-06-01

The bioavailability of methylepoxyproscillaridin (P35): a new semisynthetic cardiac glycoside.

J Bonelli, W Waginger, F Gazo

Index: Int. J. Clin. Pharmacol. Ther. Toxicol. 26(6) , 297-9, (1988)

Full Text: HTML

Abstract

The pharmacokinetic data of methylepoxyproscillaridin (3'-methyl-4'-5'-epoxyproscillaridin) (P35) after 1 mg i.v. or oral administration in two different galenic preparations (hard and soft gelatin capsules) in randomized succession were studied in 9 healthy volunteers, showing a bioavailability of 88 +/- 10.5% (soft gelatin capsule) and 81 +/- 12% (hard gelatin capsule). The half-life of P35 was calculated to be 80 +/- 13.3 h.

Related Compounds

  • Proscillaridin A

Related Articles:

Pulse pressure correlates in humans with a proscillaridin A immunoreactive compound.

1996-05-01

[Hypertension 27(5) , 1073-8, (1996)]

Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.

2009-11-01

[J. Nat. Prod. 72 , 1969-74, (2009)]

Role of endogenous cardiac glycosides in the spontaneously hypertensive rat--antagonism by active immunization.

1996-01-01

[Am. J. Hypertens. 9(1) , 81-5, (1996)]

Specific anti-digoxin Fab fragments: an available antidote for proscillaridin and scilliroside poisoning?

1990-05-01

[Hum. Exp. Toxicol. 9(3) , 191-3, (1990)]

Studies on cardiac ingredients of plants. IX. Chemical transformation of proscillaridin by utilizing its 1,4-cycloadducts as key compounds and biological activities of their derivatives.

1992-02-01

[Chem. Pharm. Bull. 40(2) , 327-32, (1992)]

More Articles...